- Home
- PRTS vs OTLK Comparison
PRTS vs OTLK Comparison
Compare PRTS & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRTS | OTLK |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 38.7M |
| IPO Year | 2006 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PRTS | OTLK |
|---|---|---|
| Price | $0.82 | $0.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $0.50 | ★ $3.83 |
| AVG Volume (30 Days) | 987.0K | ★ 1.2M |
| Earning Date | 06-08-2026 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,726.70 |
| Revenue Next Year | N/A | $80.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.38 |
| 52 Week High | $1.36 | $3.39 |
Technical Indicators
Market Signals| Indicator | PRTS | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 69.09 | 43.39 |
| Support Level | $0.70 | $0.39 |
| Resistance Level | $0.93 | $0.46 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 70.70 | 70.06 |
Price Performance
Historical ComparisonAbout PRTS CarParts.com Inc.
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.